Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain. The new drug represents a potentially significant advancement in pain management, offering an alternative to traditional opioid-based treatments.

Wealth anchor Brad Smith is joined by Seana Smith to break down the details.

To watch more expert insights and analysis on the latest market action, check out more Wealth here.

This post was written by Angel Smith